Nisha Narula1, Thomas A Aloia2. 1. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Herman Pressler Drive, Unit 1484, Houston, TX, 77030, USA. 2. Department of Surgical Oncology, University of Texas MD Anderson Cancer Center, 1400 Herman Pressler Drive, Unit 1484, Houston, TX, 77030, USA. taaloia@mdanderson.org.
Abstract
BACKGROUND: Liver resection of benign, primary, and metastatic tumors is challenging and places patients at risk of postoperative liver insufficiency. This risk is largely dependent on the volume and function of the future liver remnant (FLR). It is, therefore, critical that hepatobiliary surgeons are well versed in the measurement of liver volume and function, as well as various techniques for preoperative liver volume augmentation. PURPOSE: This comprehensive review of portal vein embolization (PVE) begins with an overview of FLR measurement and progresses to patient factors to consider when choosing PVE and assessment of hypertrophy. PVE techniques and complications are subsequently discussed. CONCLUSIONS: The absolute volume of FLR required to avoid postoperative liver insufficiency is dependent on the patient, disease, and anatomic factors. Rapid expansion of the FLR can be achieved with PVE of contralateral liver segments. Although multiple metrics have been used to correlate hypertrophy with postoperative outcomes after PVE, the kinetic growth rate (KGR) is the most reliable predictor of freedom from postoperative liver insufficiency. PVE is now considered a safe and effective procedure when performed at high-volume hepatobiliary centers. It is an effective tool that, by lowering the risk of liver failure, increases the number of patients who can undergo potential curative hepatectomy.
BACKGROUND: Liver resection of benign, primary, and metastatic tumors is challenging and places patients at risk of postoperative liver insufficiency. This risk is largely dependent on the volume and function of the future liver remnant (FLR). It is, therefore, critical that hepatobiliary surgeons are well versed in the measurement of liver volume and function, as well as various techniques for preoperative liver volume augmentation. PURPOSE: This comprehensive review of portal vein embolization (PVE) begins with an overview of FLR measurement and progresses to patient factors to consider when choosing PVE and assessment of hypertrophy. PVE techniques and complications are subsequently discussed. CONCLUSIONS: The absolute volume of FLR required to avoid postoperative liver insufficiency is dependent on the patient, disease, and anatomic factors. Rapid expansion of the FLR can be achieved with PVE of contralateral liver segments. Although multiple metrics have been used to correlate hypertrophy with postoperative outcomes after PVE, the kinetic growth rate (KGR) is the most reliable predictor of freedom from postoperative liver insufficiency. PVE is now considered a safe and effective procedure when performed at high-volume hepatobiliary centers. It is an effective tool that, by lowering the risk of liver failure, increases the number of patients who can undergo potential curative hepatectomy.
Authors: E Simoneau; M Hassanain; M Shaheen; M Aljiffry; N Molla; P Chaudhury; S Anil; A Khashper; D Valenti; P Metrakos Journal: Br J Surg Date: 2015-06-24 Impact factor: 6.939
Authors: Yoji Kishi; Eddie K Abdalla; Yun Shin Chun; Daria Zorzi; David C Madoff; Michael J Wallace; Steven A Curley; Jean-Nicolas Vauthey Journal: Ann Surg Date: 2009-10 Impact factor: 12.969
Authors: Swee H Teh; John Christein; John Donohue; Florencia Que; Michael Kendrick; Michael Farnell; Stephen Cha; Patrick Kamath; Raymond Kim; David M Nagorney Journal: J Gastrointest Surg Date: 2005-12 Impact factor: 3.267
Authors: Pim B Olthof; Luca Aldrighetti; Ruslan Alikhanov; Matteo Cescon; Bas Groot Koerkamp; William R Jarnagin; Silvio Nadalin; Johann Pratschke; Moritz Schmelze; Ernesto Sparrelid; Hauke Lang; Alfredo Guglielmi; Thomas M van Gulik Journal: Ann Surg Oncol Date: 2020-02-26 Impact factor: 5.344
Authors: Noemi Daradics; Pim B Olthof; Andras Budai; Michal Heger; Thomas M van Gulik; Andras Fulop; Attila Szijarto Journal: Curr Oncol Date: 2021-12-09 Impact factor: 3.677